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Abstract
Introduction: The mono- and digalactosyldiacylglycerol (MGDG and DGDG) galactolipids have been purified from
the thermophilic blue-green alga Phormidium sp. ETS-05 that colonizes the therapeutic thermal mud of Abano
Terme and Montegrotto Terme, Italy. Both compounds present a marked composition in polyunsaturated fatty
acids, mainly omega-3. The therapeutic thermal mud is applied mainly to osteoarthritic cartilage patients. In the
present study the effect of MGDG treatment on proteins and factors expressed by human articular cartilage cells in
culture and on pathways activated in inflammatory conditions was studied.
Methods: Primary cultures of human articular chondrocytes were used at cell passage number 1 (P1). Cells were
treated in serum-free medium with inflammatory cytokines in the presence and in the absence of MGDG. Western
blot was performed on collected medium and on cell layers. At least three different experiments were performed
on primary cultures. The quantitation of the MGDG effect was performed by densitometric scanning of Western
blots. p38 Mitogen Activated Protein Kinase (p38) activation, Nuclear Factor-kappaB (NF-kB) activation and
Prostaglandin E2 (PGE2) quantitation were performed by commercially available assays. Results are given as the
mean values ± SD. All statistical analyses were performed using GraphPad software. The two-tailed Student’s t -test
was performed.
Results: We report that MGDG: 1) represses the expression of interleukin-6 (IL-6) and interleukin-8 (IL-8) induced by
interleukin-1alpha (IL-1a) or IL-1a + tumor necrosis factor a (TNFa) interfering with the p38 and NF-kB pathways;
2) is not toxic for the cells and does not affect the cell phenotype; 3) strongly enhances COX-2 expression induced
by IL-1a or IL-1a + TNFa; 4) represses mPGES expression induced by IL-1a and the synthesis of PGE2 and induces
the synthesis of 15-deoxy-Δ 12,14-prostaglandin J2 (15ΔPGJ2). In addition, the COX-2 product 15ΔPGJ2 added to the
cells: 1) strongly represses IL-6 and IL-8 induced by IL-1a; 2) represses mPGES expression induced by IL-1a and the
synthesis of PGE2.
Conclusions: All together these data suggest that MGDG has an anti-inflammatory activity in human articular
cartilage and possibly activates an anti-inflammatory loop triggered by COX-2 via 15ΔPGJ2 production, indicating a
possible role of COX-2 in resolution of inflammation. The purified compound is a novel anti-inflammatory agent
potentially active for human articular cartilage pathologies related to inflammation.
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MGDG and DGDG (mono- and digalactosyldiacylgly-
cerol galactolipids with a high content of polyunsatu-
rated fatty acids, mainly omega-3 s) are the most
widespread non-phosphorous polar lipids in the bio-
sphere and account for 80% of the membrane lipids
found in green plant tissues. In contrast with mem-
branes of animals and yeasts where phospholipids are
abundantly represented, these lipids are major constitu-
ents of the photosynthetic membranes of higher plants,
algae and bacteria [1]. In animals, MGDG and DGDG
are present at low concentration, particularly in the
myelin and in oligodendrocytes [2]. Among specific bio-
logical activities, including anti-viral [3], anti-tumor and
anti-proliferative activity [4,5], this class of compounds
revealed an anti-inflammatory activity in vitro by inhi-
biting the generation of a superoxide anion in primed
leucocytes, showing an inhibitory effect on the chemo-
taxis of human peripheral blood neutrophils in vitro
[5,6]. An acute in vivo anti-inflammatory activity of this
compound in a murine chronic dermatitis model was
also reported [7]. MGDG and DGDG have been purified
from the thermophilic blue-green alga Phormidium sp.
ETS-05 that colonizes the therapeutic thermal mud of
Abano Terme and Montegrotto Terme, Italy [8]. The
therapeutic thermal mud is applied mostly to osteoar-
thritic cartilage patients. An in vivo anti-inflammatory
activity of the purified compounds has been demon-
strated in both the croton-oil-induced ear edema and
the carrageenan-induced paw edema mouse models [9].
Indeed, some anti-inflammatory action of the thermal
mud was described also in patients by monitoring the
level of inflammatory cytokines in their serum [10], but
studies on a possible specific anti-inflammatory action
of the purified compounds at the level of the articular
cartilage are missing. In a recent publication, we tested
the anti-inflammatory role of MGDG in an avian model
and we showed that the treatment of avian articular
chondrocytes with MGDG suppressed the expression of
the inflammation induced proteins Ex-FABP, Avidin,
and Serum Amyloid A (SAA), in agreement with a
strong anti-inflammatory property of MGDG [11].
In a previous study we described the synthesis of IL-
6 and IL-8 by human articular cartilage chondrocytes
following induction with IL-1a,T N F a, and the combi-
nation of the two cytokines [12]. We also reported the
existence of an anti-inflammatory pathway involving
COX-2 in the MC615 murine chondrocytic cell line
[13]. We previously showed that in the mouse chon-
drocytic cell line MC615 both NF-kB and p38 depen-
dent pathways are activated in response to an
inflammatory stimulus and that p38 is involved in the
NF-kB activation [14,15]. In the present study we
investigated the effect of the MGDG treatment on
human articular chondrocytes and we showed an inhi-
bition of the IL-6 and IL-8 expression induced by
inflammatory cytokines concomitant to an enhance-
ment of the COX-2 expression. The possible pathways
involved in inflammation and modulated by the
MGDG treatment were investigated.
Materials and methods
Materials
IL-1a and TNFa were from PeproTech, Rocky Hill,
N J ,U S A .1 5 - d e o x y - Δ
12,14-prostaglandin J2 (15ΔPGJ2),
anti-COX-2 polyclonal antiserum and anti-mPGES-1
antibodies were from Cayman Chemical (Ann Arbor,
MI, USA). Anti-IL-6, anti-IL-8 and anti-actin antibo-
dies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Anti-actin antibody was raised
against a peptide mapping at the C-terminus of actin
of human origin and was reactive against both actin
isoforms. Antibody against type I collagen was pur-
chased from Developmental Studies Hybridoma Bank
(Iowa City, IA, USA) and antibody against type II col-
lagen was from NeoMarkers (Fremont, CA, USA).
SB203580 was purchased from Calbiochem (Darmstadt,
Germany), BAY117082 was obtained from Sigma (St.
Louis, MO, USA).
MGDG preparation
MGDG was extracted from cultures of the Phormidium
sp13 ETS-05 cyanobacterium isolated from the thermal
mud of Abano Terme and Montegrotto Terme, Padua,
Italy as described [8]. Fresh biomasses from laboratory
cultures of ETS-05 were frozen and freeze-dried. A total
lipidic extract was obtained by treating the dry material
with a chloroform/methanol/water mixture (100:50:7 v/
v). This extract was washed with water and dried under
vacuum. The residue was further fractioned between n-
hexane and 10% water/methanol. The n-hexane layer
was discarded and the water/methanol layer was dried.
Chromatographically pure MGDG was obtained from
this crude polar lipidic fraction by flash chromatography
in a silica gel column using a chloroform/methanol/
water/acetic acid mixture (90:10:2.5:0.5 v/v) as eluent.
The identity and purity of the compound was checked
by NMR and ESI-MS. MGDG was dissolved in absolute
ethanol and supplemented to the cell culture medium at
the indicated concentrations. Ethanol concentration in
cell culture medium was 1:1000.
Cell culture and MGDG treatment
Femoral heads of adult patients after joint replacement
surgery were obtained by the Ospedale S. Antonio
Recco, ASL 3 Genovese, Genova, Italy with previous
Ulivi et al. Arthritis Research & Therapy 2011, 13:R92
http://arthritis-research.com/content/13/3/R92
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ing legislation, at the time the work was performed
ethics approval was not required for left-over material
derived from surgery.
The work was performed on 19 primary cultures
derived from hip replacement surgery mostly from old
patients that had a fracture of the femur or severe
osteoarthritis. The range of age was 58 to 74. Only two
patients were 17- and 21-years-old and had surgery fol-
lowing a car accident. The cartilage of old patients was
thin in the areas of contact with the joint. Articular car-
tilage was taken from suitable less degraded areas. We
did not observe striking differences in the response to
inflammatory and anti-inflammatory agents of the cul-
tured cells between old and young patients. Articular
cartilage was isolated, cleared of connective tissue and
subchondral bone, minced in small pieces and rinsed in
phosphate-buffered saline (PBS pH 7.2). Single chondro-
cytes were released by repeated enzymatic digestions (1
mg/ml hyaluronidase, 400 U/ml collagenase I, 1000 U/
ml collagenase II, 0.25% trypsin in PBS). Isolated cells
were pooled and cultured in adhesion in F12 culture
medium containing 10% FCS.
All cultures were treated at P1 passage. Cells were
washed with PBS and incubated 24 hours in serum free
medium with the indicated concentrations of MGDG.
The medium was then replaced with fresh medium sup-
plemented with MGDG and inflammatory cytokines (IL-
1a +T N F a or IL-1a alone). Incubation was performed
for 24 hours after which the cell conditioned medium
was collected and analyzed.
Western blot analysis
For protein identification, medium aliquots were loaded
on a 15% SDS-PAGE. Electrophoresis was performed in
reducing conditions. After electrophoresis, the gel was
blotted to a BA85 nitrocellulose membrane (Schleicher
and Schuell GmbH, Dassel, Germany) according to the
procedure described by [16]. The blot was saturated for
16 hours with 5% non-fat cow milk in TTBS buffer (20
mM Tris HCl pH 7.5, 500 mM NaCl, 0.05% Tween 20),
washed several times with TTBS and incubated for two
hours at room temperature with specific antibodies
raised in rabbit. After washing, the detection was per-
formed by a conjugated HRP-anti-rabbit IgG (Amer-
sham, Buckinghamshire, UK) for one hour at room
temperature. The blot was washed with TTBS and incu-
bated with an enhanced chemio-luminescence substrate
mixture (Amersham). The blot was then exposed to an
X-ray film (Amersham) in order to obtain the image.
Molecular analysis
Total RNA was extracted from human articular cartilage
using Trizol Reagent according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA, USA). Reverse
transcription reactions were performed in a 20 μl
volume with 2 μgo ft o t a lR N A .A1 : 1 0d i l u t i o no ft h e
resulting cDNA was used as a template to quantify the
relative content of mRNA by real-time PCR (ABI
PRISM 7700 Sequence
Detection System) using respective primers and SYBR
Green. The following primers for real-time PCR were
designed using Primer Express software:
GAPDH: forward 5’-AAAGTCGGAGTCAACG-
GATTTG-3’
reverse 5’-TGTAAACCATGTAGTTCAGATC-
GATGA-3’
Type II Coll: forward 5’-CGGCTGCACAAAACA-
CACTGC-3’
reverse 5’-CCTTCCGCCCTGCAGAT-3’
Type I Coll: forward 5’- CAGCCGCTTCACCTA-
CAGC-3’
reverse 5’- TTTTGTATTCAATCACTGTCTTGCC-3’
Viability test
Articular chondrocytes were seeded in standard plastic
culture dishes at a concentration of 12 × 10
3/cm
2 and
treated with MGDG and cytokines as described. To
determine cell viability the tyazolyl blue (MTT, Sigma)
method was used. The culture medium was removed and
replaced with 1 ml of serum-free medium supplemented
with 25 μlo fM T Ts t o c ks o l u t i o n( 5m g / m l ) .A f t e rf o u r
hours incubation the medium was discarded and the con-
verted dye was solubilized with 1 ml of absolute ethanol.
Dye absorbance was measured at 570 nm.
p38 determination
p38 determination was performed with the p38 Elisa kit
by Active Motif, Carlsbad, CA, USA, that allows
researchers to determine activated p38, total p38 and
cell number, providing a sensitive and accurate measure.
NF-kB activation
Binding of the NF-kB p65 subunit to the NF-kB binding
consensus sequence 5’- GGGACTTTCC-3’ was mea-
sured with the ELISA-based Trans Am NF-kB kit
(Active Motif, Carlsbad, CA, USA) using whole cell
lysates prepared from chondrocyte cultures. Preparation
of cell extracts was done as recommended by the manu-
facturer. The Trans-Am kit employs 96-well microtiter
plates coated with an oligonucleotide containing the
NF-kB binding consensus sequence. The active form of
the p65 subunit in the whole cell lysates was detected
using antibodies specific for an epitope that is accessible
only when the subunit is activated and bound to its tar-
get DNA. Specificity was checked by measuring the abil-
ity of soluble wild-type or mutated oligonucleotides to
inhibit binding. Results are expressed as specific binding,
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sence of the mutated oligonucleotide minus those
observed in the presence of the wild-type oligonucleo-
tide. All measurements were performed in triplicate.
PGE2 quantitation
Cell cultures were treated for 24 hours with MGDG 25
μM, the medium was then removed and MGDG 25 μM
+I L - 1 a (100 U/ml) in serum-free condition was added
for 24 hours. Control cultures, that is, untreated and
only MGDG or only IL-1a treated, were performed in
parallel. After the 24-hour incubation the supernatants
were collected, centrifuged to remove particulate matter
a n ds t o r e da t- 8 0 ° C .A l i q u o t sw e r ea s s a y e df o rP G E 2
content using a PGE2-specific competitive EIA kit-
Monoclonal (Cayman Chemical, Ann Arbor, MI, USA)
according to the manufacturer’s instructions. Each sam-
ple was measured in triplicate in two dilutions. Statisti-
cal analysis of the data was performed.
15ΔPGJ2 quantitation
15ΔPGJ2 quantitation was performed using a 15ΔPGJ2
-specific competitive EIA kit (Enzo Life Sciences, Inc,
Ann Harbor, MI, USA) according to the manufacturer’s
instructions. Measurements were performed on cell
serum-free media obtained as described for PGE2 quan-
titation. Each sample was measured in triplicate.
Statistic
In this study, results are given as the mean values ± SD.
All statistical analyses were performed using GraphPad
software. The two-tailed Student’s t-test was performed.
A value of P < 0.05 was considered significant.
Results
MGDG represses the inflammatory response induced in
human articular cells by IL-1a + TNFa without
impairment of cell viability
In a previous study on human articular cartilage cells,
we described the induction of IL-6 and IL-8 expression
by treatment of the chondrocytes with IL-1a,T N F a,
or the combination of the two [12]. In the present
work, to study a possible anti-inflammatory activity of
MGDG in cartilage, we pretreated cultures of articular
cartilage cells at Passage 1 with different concentra-
tions of the compound for 24 hours before the replace-
ment of the medium with the medium containing
IL-1a +T N F a in addition to MGDG for 24 hours.
The Western blot of the cell culture media confirmed
a strong induction of IL-6 and IL-8 by inflammatory
cytokine treatment. Interestingly, the induction was
repressed by the MGDG pre-treatment with a clear
dose response mode (Figure 1A). A quantitation of the
repression of the inflammatory response proteins IL-6
and IL-8 by MGDG was performed by the densito-
metric analysis of five Western blots performed on five
independent experiments on two different chondrocyte
primary cultures. To show the repression by MGDG,
the % value referred to the value in IL-1a +T N F a
induced cells (100%) was calculated (Figure 1B, C).
The repression by MGDG was statistically significant
for both proteins at the two MGDG concentrations
(P < 0.0001). Cell viability was determined by MTT
staining of the cells treated with IL-1a +T N F a in the
absence and in the presence of MGDG at different
concentrations. The MGDG supplement did not affect
cell viability at any concentration (Figure 1D). Deter-
mination of the cell viability was performed on tripli-
cate dishes in two independent experiments with the
same result.
Figure 1 MGDG (monogalactosyldiacylglycerol) anti-
inflammatory activity on IL-1a (interleukin-1alpha) + TNFa
(Tumor Necrosis Factor alpha) treated cells. Cells were
pretreated overnight with different concentrations of MGDG before
treatment with 100 U/ml IL-1a + 200 U/ml TNFa for 24 hours. A)
Upper panels: Western blot of articular cartilage cell lysates with
COX-2 (Cyclooxygenase-2) antibody. Actin was blotted as an internal
control. Lower panels: Western blot of cell conditioned media with
IL-6 (interleukin-6) and IL-8 (interleukin-8) antibodies; B-C)
Quantitation of the IL-6 and IL-8 repression by MGDG; densitometric
analysis of five Western blots performed on five independent
experiments on two chondrocyte primary cultures; to show the
repression by MGDG the % value referred to the value in IL-1a
+TNFa induced cells (100%) is calculated. Average ± standard
deviation is shown. D) MTT staining of cells treated with IL-1a
+TNFa in the absence and in the presence of MGDG. The
experiment was performed in triplicate in two independent
experiments giving similar results. One representative experiment is
shown. 15ΔPGJ2, 15-deoxy-Δ
12,14-prostaglandin J2,; COX-2,
cyclooxygenase-2; DGDG, digalactosyldiacylglycerol; IL-1, interleukin-
1; IL-6, interleukin-6; IL-8, interleukin-8; MGDG,
monogalactosyldiacylglycerol; mPGES, microsomal PGE synthase; NF-
kB, nuclear factor-kappaB; P1, cell passage number1; p38, p38
mitogen activated protein kinase; PGE2, prostaglandin E2; TNFa,
tumor necrosis factor alpha.
Ulivi et al. Arthritis Research & Therapy 2011, 13:R92
http://arthritis-research.com/content/13/3/R92
Page 4 of 12MGDG represses the inflammatory response induced in
human articular cells by IL-1a
In order to identify the possible inflammatory pathway
repressed by the MGDG treatment, adult articular cells
were treated with either IL-1a or TNFa in order to dis-
tinguish the specific action of each of the two cytokines.
By Western blot we showed that at the normally used
concentrations IL-1a was responsible for the induction
of both IL-6 and IL-8, although an increased effect was
observed by the contemporary treatment with TNFa
thus suggesting a synergistic action of the two cytokines
(Figure 2A). MGDG repressed the induction of IL-6 and
IL-8 by IL-1a (Figure 2B, C, D). The repression by
MGDG was statistically significant for both proteins (P
< 0.0001).
MGDG sustains Collagen II expression in IL-1a treated
cells
MGDG and IL-1a treated articular chondrocytes were
tested for the expression of the cartilage specific Col-
lagen II and Collagen I. A Real Time RT-PCR analysis
was performed on the extracted mRNAs. The expression
of Collagen II, significantly reduced by the IL-1a treat-
ment was restored by the MGDG pre-treatment with a
clear dose response mode, suggesting a protection of the
cartilage phenotype as consequence of the presence of
the MGDG supplement in the culture medium (Figure
2E). Type I collagen expression did not show a signifi-
cant modulation by MGDG (Figure 2F). Western blot
analyses are in agreement with the results obtained by
Real Time RT-PCR analysis (Figure 2E, F insets)
Repression of inflammatory pathways by MGDG in
cultured chondrocytes
We previously demonstrated that in the mouse chon-
drocytic cell line MC615 a pathway involving p38 and
NF-kB is activated in inflammation [13,15]. In order to
investigate the possible signaling pathways repressed by
MGDG in inflammation we treated the cartilage cells
with IL-1a in the absence and in the presence of either
p38 or NF-kB inhibitors.
p38 pathway is involved in IL-6 and IL-8 production and
is repressed by MGDG
A repression of IL-6 and IL-8 was observed by treat-
ment with SB203580 a specific inhibitor of p38 (Figure
3A, B). The repression was considered statistically sig-
nificant (P < 0.0001).
Therefore, we wanted to measure the activation of p38
taking advantage of a commercially available ELISA
assay that allows determination of phospho-p38, total
p38 and cell number in the same assay. Cells were trea-
ted with IL-1a in the absence and in the presence of 20
μM MGDG. Based on the results of a preliminary time
course experiment (10, 30 and 60 minutes - not shown)
the assay was performed at 60 minutes. The results are
shown in Figure 3C. MGDG treatment repressed the IL-
1a induced increase of the phospo-p38 by 75.71% but
also the total p38 protein was repressed by 36.77% while
the cell number remained unchanged. The observed
repression was statistically significant (P < 0.0001).
NF-kB pathway is involved in IL-6 and IL-8 production
and is inhibited by MGDG
A repression of IL-6 and IL-8 was also observed treating
the cells with BAY-117082, an inhibitor of NF-kB activa-
tion, suggesting an involvement of NF-kB in the IL-6
Figure 2 MGDG (monogalactosyldiacylglycerol) anti-
inflammatory activity on IL-1a (interleukin-1alpha) treated
cells. A) Human articular chondrocytes were treated with 100 U/ml
IL-1a (Interleukin-1alpha) and/or 200 U/ml TNFa (Tumor Necrosis
Factor alpha) for 24 hours. Western blot analysis of chondrocyte
conditioned media with IL-6 (Interleukin-6), IL-8 (Interleukin-8)
antibodies; B) Cells were pretreated 24 hours with 25 μM MGDG
before treatment with IL-1a for 24 hours. Upper panels: Western
blot of chondrocyte lysates with COX-2 (Cyclooxygenase-2)
antibody. Actin was blotted as an internal control. Lower panels:
Western blot of conditioned media with IL-6 and IL-8 antibodies; C-
D) Quantitation of the repression of IL-6 and IL-8 by MGDG. The
average of densitometric analysis of Western blots performed in six
determinations on three primary cultures of human chondrocytes in
duplicate dishes. To show the repression by MGDG the % value
referred to the value in IL-1a induced cells (100%) is calculated. E,
F) Real Time RT-PCR analysis of Collagen II and Collagen I mRNA
expression in human articular chondrocytes treated with 100 U/ml
IL-1a in the absence and in the presence of MGDG at different
concentrations. Insets show Western blot analysis of chondrocyte
conditioned media with Collagen type II and Collagen type I
antibodies. 15ΔPGJ2, 15-deoxy-Δ
12,14-prostaglandin J2; COX-2,
cyclooxygenase-2; DGDG, digalactosyldiacylglycerol; IL-1, interleukin-
1; IL-6, interleukin-6; IL-8, interleukin-8; MGDG,
monogalactosyldiacylglycerol; mPGES, microsomal PGE synthase; NF-
kB, nuclear factor-kappaB; P1, cell passage number1; p38, p38
mitogen activated protein kinase; PGE2, prostaglandin E2; TNFa,
tumor necrosis factor alpha.
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was measured by a commercial kit based on the binding
of the NF-kB p65 subunit to the NF-kB binding consen-
s u ss e q u e n c e( F i g u r e4 D ,E ) .T h ee x p e r i m e n ts h o w e da
strong induction of NF-kB activation by the IL-1a treat-
ment and a repression of the p65 binding by MGDG of
31% ± 4.39 statistically significant (P < 0.0001).
COX-2 expression is induced by treatment with IL-1a and
enhanced by MGDG treatment
Since COX-2 is part of the inflammatory response in
cartilage [16], we monitored the expression of COX-2 in
our experimental conditions. In all performed experi-
ments, we observed that in cartilage cells COX-2 was
induced by the treatment with IL-1a +T N F a or with
IL-1a only and that its expression was strongly
enhanced when cells were supplemented with MGDG
before the inflammatory cytokine (CKs) addition. On
the contrary, in the same experiments the expression of
IL-6 and IL-8 was always strongly repressed (Figure 1,
Figure 3 MGDG (monogalactosyldiacylglycerol) represses p38
(p38 Mitogen Activated Protein Kinase), involved in IL-6
(Interleukin-6) and IL-8 (Interleukin-8) production. A) Inhibition
of IL-6 and IL-8 synthesis by the p38 inhibitor SB 203580. Human
chondrocytes were treated with 10 μM SB203580 for two hours
before being supplemented with 100 U/ml IL-1a for 20 hours in the
presence of SB203580. Conditioned media were collected and IL-6
and IL-8 synthesis was analyzed by Western blot; B) Quantitation of
the inhibition by the MGDG of the IL-6 and IL-8 synthesis. The
average of the densitometric analysis of five western blots
performed in five independent experiments on four different
primary cultures is presented. To show the repression by SB203580
the % value referred to the value in IL-1a induced cells (100%) is
calculated. C) MGDG inhibition of p38 phosphorylation. Human
chondrocytes were treated with 100 U/ml IL-1a in the absence and
the presence of 20 μM MGDG for 60 minutes. Phosphorylation of
p38 and native inactive protein levels were assayed using the FACE
p38 Kit. The average of two independent experiments performed in
triplicate are shown. The number of cells in each well was
determined using Crystal Violet according to the manufacturer’s
instructions. To show the repression by MGDG the % value referred
to the value in IL-1a induced cells (100%) is calculated. 15ΔPGJ2,
15-deoxy-Δ
12,14-prostaglandin J2; COX-2, cyclooxygenase-2; DGDG,
digalactosyldiacylglycerol; IL-1, interleukin-1; IL-6, interleukin-6; IL-8,
interleukin-8; MGDG, monogalactosyldiacylglycerol; mPGES,
microsomal PGE synthase; NF-kB, nuclear factor-kappaB; P1, cell
passage number1; p38, p38 mitogen activated protein kinase; PGE2,
prostaglandin E2; TNFa, tumor necrosis factor alpha.
Figure 4 MGDG (monogalactosyldiacylglycerol) inhibits NF-kB
(Nuclear Factor-kappaB) involved in IL-6 (Interleukin-6) and IL-
8 (Interleukin-8) production. A) Inhibition of IL-6 and IL-8
synthesis by the NF-kB inhibitor BAY117082. Human chondrocytes
were treated with 5 μM BAY117082 for two hours before being
supplemented with 100 U/ml IL-1a for 20 hours in the presence of
BAY117082. Conditioned media were subjected to immunoblot
analysis using IL-6 and IL-8 polyclonal antibodies; B-C) Quantitation
of the inhibition by BAY117082 of the IL-6 and IL-8 synthesis. The
average of the densitometric analysis of four Western blots
performed on four independent experiments on two different
primary cultures is presented. To show the repression by BAY117082
the % value referred to the value in IL-1a induced cells (100%) is
calculated. D) NF-kB activity inhibition by MGDG. Human
chondrocytes were pretreated overnight with 25 μM MGDG and
stimulated with 100 U/ml IL-1a in serum free conditions for 24
hours. 5 μg of whole cell lysates were tested for binding of the
activated p65 NF-kB subunit to a NF-kB consensus sequence using
the Trans-Am NF-kB ELISA kit. Results are expressed as specific
binding. Two experiments on two different primary cultures were
performed in triplicate dishes, each one assayed in triplicate. One
representative experiment is shown; E) To show the repression by
MGDG the % value referred to the value in IL-1a induced cells
(100%) is calculated. Each value was subtracted of the basal value.
The average of the two experiments performed in triplicate and
assayed in triplicate is shown. 15ΔPGJ2, 15-deoxy-Δ
12,14-
prostaglandin J2; COX-2, cyclooxygenase-2; DGDG,
digalactosyldiacylglycerol; IL-1, interleukin-1; IL-6, interleukin-6; IL-8,
interleukin-8; MGDG, monogalactosyldiacylglycerol; mPGES,
microsomal PGE synthase; NF-kB, nuclear factor-kappaB; P1, cell
passage number1; p38, p38 mitogen activated protein kinase; PGE2,
prostaglandin E2; TNFa, tumor necrosis factor alpha.
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formed on three different experiments revealed a 8.26 ±
1.23-fold increase (statistically significant; P = 0.0005) of
the COX-2 expressed by cells treated with MGDG 25
μM + CKs over the COX-2 expressed by cells treated
with CKs and no supplement of MGDG. In agreement
with these data, also the COX-2 expression by cells trea-
ted with MGDG 25 μM + IL-1a compared to the COX-
2 expressed by cells treated with only IL-1a showed an
increase of 6.84 ± 2.19 (statistically significant; P =
0.0099) Figure 5B.
mPGES expression and PGE2 production is induced by IL-
1a and inhibited by MGDG treatment
Since mPGES is induced in cartilage in pathological and
inflammatory conditions [13,17] we probed the mem-
branes with antibodies against the protein. mPGES was
expressed in cartilage cells treated with IL-1a and was
repressed in the MGDG pre-treated cells (Figure 5A, C).
In agreement with this finding PGE2 production was
strongly induced by the IL-1a treatment and signifi-
cantly repressed by the MGDG pre-treatment (Figure
5D). Two experiments were performed in triplicate
dishes, each one assayed in triplicate. The first experi-
ment showed a calculated repression of 49% ± 10.25
after subtraction of the basal level. The second experi-
ment showed a calculated repression of 83.6% ± 11.26
after subtraction of the basal level. In both experiments
the repression was considered statistically significant (P
< 0.0001).
I ts h o u l db en o t e dt h a ti nt h es a m ec e l l sw h e r e
mPGES expression was inhibited, COX-2 expression
was strongly induced (Figure 5A, B), suggesting that a
different pathway of prostaglandin other than the PGE2
production was functioning in these cells, possibly lead-
ing to 15ΔPGJ2 production.
15ΔPGJ2 production is induced by MGDG treatment in IL-
1a treated cells
There is increasing evidence of COX-2 involvement in
the resolution of inflammation via its product 15ΔPGJ2
[18,19].
Since in the same cells where mPGES expression and
PGE2 production was inhibited COX-2 expression was
strongly induced (Figure 5 A, B), we investigated the
effect of MGDG on 15ΔPGJ2 production. As shown in
Figure 5E 15ΔPGJ2 production was moderately induced
by either MGDG or IL-1a but was strongly increased by
MGDG in the presence of IL-1a.
15ΔPGJ2 represses IL-6, IL-8 and mPGES expression
induced in inflammatory conditions
Therefore, we investigated the activity of 15ΔPGJ2 on
the expression of IL-6 and IL-8 in cartilage cells treated
with IL-1a. A strong decrease in the expression of IL-6
and IL-8 induced by IL-1a was observed after treatment
with 15ΔPGJ2 (Figure 6). Densitometric scanning of
three Western blots performed on three different pri-
mary cultures showed a repression statistically signifi-
cant (P < 0.0001). In the same cells a decrease of
mPGES was also observed (Figure 7A, B). Densitometric
scanning of three Western blots performed on three dif-
ferent primary cultures showed a repression statistically
significant (P = 0.0002). In agreement with these data
Figure 5 Effect of MGDG (monogalactosyldiacylglycerol)
treatment on pathways of prostaglandins production in
cultured articular chondrocytes. A) Human chondrocytes were
pretreated overnight with 25 μM MGDG before treatment with 100
U/ml IL-1a for 24 hours. Upper panel: cell lysates were collected
and analyzed by Western blot with a COX-2 polyclonal antibody.
Middle panel: Western blot of cell lysates using a mPGES polyclonal
antibody. Actin was blotted as an internal control; B) Quantitation
of COX-2 expression in IL-1a + MGDG treated cells calculated as
fold increase related to IL-1a only treatment. The average of three
Western blots from three different primary cultures is shown; C)
Quantitation of the inhibition of mPGES expression by the MGDG
treatment. To show the repression by MGDG the % value referred
to the value in IL-1a induced cells (100%) is calculated. The average
of two Western blots from two different primary cultures is shown;
D) PGE2 production. Conditioned media collected from human
chondrocytes were analyzed for prostaglandin E2 content by a
competitive immunoassay using the prostaglandin E2 EIA kit
Monoclonal. Two experiments were performed in triplicate dishes,
each one assayed in triplicate. One representative experiment is
shown. Concentrations are expressed in pg/ml. E)1 5 ΔPGJ2
quantitation. 15ΔPGJ2 was measured in cell serum-free media using
a1 5 ΔPGJ2 -specific competitive EIA Kit. Two experiments were
performed, each one assayed in triplicate. One representative
experiment is shown. Concentrations are expressed in pg/ml.
15ΔPGJ2, 15-deoxy-Δ
12,14-prostaglandin J2,; COX-2, cyclooxygenase-2;
DGDG, digalactosyldiacylglycerol; IL-1, interleukin-1; IL-6, interleukin-
6; IL-8, interleukin-8; MGDG, monogalactosyldiacylglycerol; mPGES,
microsomal PGE synthase; NF-kB, nuclear factor-kappaB; P1, cell
passage number1; p38, p38 mitogen activated protein kinase; PGE2,
prostaglandin E2; TNFa, tumor necrosis factor alpha.
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ment (Figure 7C). Two experiments were performed in
triplicate dishes, and each one assayed in triplicate. The
first experiment showed a calculated repression of 53.3%
after subtraction of the basal level, considered statisti-
cally significant (P < 0.0001). The second experiment
showed a calculated repression of 76.56% after subtrac-
tion of the basal level considered statistically significant
(P = 0.0006).
These data suggest that the 15ΔPGJ2 treatment drives
prostaglandin synthesis toward PGD2 and derivatives
possibly establish an anti-inflammatory loop.
Discussion
IL-8 and IL-6 are among the key regulatory molecules of
cartilage destruction in rheumatoid arthritis [20] and are
present in synovial fluid of patients with osteoarthritis
[21]. In a previous study on young, aged and osteoar-
thritic human articular cartilage, we described the
induction of IL-8 and IL-6 by treatment of the cultured
chondrocytes with IL-1a,T N F a, and the combination
of the two [12]. It has been reported that both cytokines
have a detrimental effect on articular cartilage. Indeed,
IL-8 regulates leukocyte activation through p38 mito-
gen-activated protein kinase signaling [22], is one of the
most potent chemotactic factors for neutrophils [23],
and triggers neutrophil accumulation and destruction of
cartilage [24]. It has also been reported that IL-8, which
is up-regulated in OA cartilage chondrocytes, is involved
in articular chondrocyte hypertrophic differentiation
through p38 mitogen-activated protein kinase signaling
causing the synthesis of an altered matrix and patholo-
gic calcification in OA [25].
Increasing evidence suggests that IL-6 and its soluble
receptor are involved in both inflammatory and degen-
erative joint diseases. Increased levels of IL-6 and sIL-6R
have been found in synovial fluids and sera from
osteoarthritis and rheumatoid arthritis patients [21] and
their level correlates with the increased leukocyte infil-
tration in synovial tissue [26]. Furthermore, in IL-6-defi-
cient mice immunized with type II collagen, a decrease
of inflammatory cells in knee joints and a reduced anti-
body response to type II collagen was observed, in
agreement with a crucial role played by IL-6 in the
Figure 6 15ΔPGJ2 (15-deoxy-
12,14-prostaglandin J2,) represses IL-6 (interleukin-6) and IL-8 (interleukin-8) induced by IL-1a (interleukin-
1 alpha). A) Human chondrocytes were treated, in the absence of serum, with 3 μM1 5 ΔPGJ2 for two hours before being incubated with 100
U/ml IL-1a for 24 hours in the presence of 15ΔPGJ2. A) Immunoblot analysis using IL-6 and IL-8 polyclonal antibodies were performed on
conditioned media; B) Quantitation of the inhibition by 15ΔPGJ2 of the IL-6 and IL-8 synthesis was obtained by the densitometric analysis of four
Western blots of four independent experiments performed in three different primary cultures. To show the repression by 15ΔPGJ2 the % value
referred to the value in IL-1a induced cells (100%) is calculated. Average ± standard deviation is shown. 15ΔPGJ2, 15-deoxy-Δ
12,14-prostaglandin
J2,; COX-2, cyclooxygenase-2; DGDG, digalactosyldiacylglycerol; IL-1, interleukin-1; IL-6, interleukin-6; IL-8, interleukin-8; MGDG,
monogalactosyldiacylglycerol; mPGES, microsomal PGE synthase; NF-kB, nuclear factor-kappaB; P1, cell passage number1; p38, p38 mitogen
activated protein kinase; PGE2, prostaglandin E2; TNFa, tumor necrosis factor alpha.
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Page 8 of 12development of autoimmune collagen-induced arthritis
[27]. In addition a recent study showed that IL-6 inhib-
ited type II collagen production by rabbit articular chon-
drocytes through a transcriptional control, suggesting a
m e c h a n i s mf o rt h ep h e n o t y p i cc h a n g eo c c u r r i n gi n
pathological osteoarthritic cartilage [28].
We induced an inflammatory response in adult carti-
lage cells by a treatment with IL-1a +T N F a or IL-1a
alone in the absence, and in the presence, of MGDG,
and we detected and quantified the expression of IL-6
and IL-8 by these cells. We also investigated the possible
inflammatory pathways repressed by MGDG. As shown
by the low SD observed in the different experiments, we
did not observe significant differences among the
response of the cells from different patients.
T h em a i nf i n d i n g so ft h i sw o r ka r e :1 )M G D G
represses the synthesis of IL-6 and IL-8 induced by IL-
1a + TNFa in a dose response mode in cultured human
articular chondrocytes; 2) the treatment with MGDG
does not impair cell viability and restores type II col-
lagen expression decreased in the inflammatory condi-
tion; 3) IL-1a is responsible for the induction of IL-6
and IL-8, although a stronger effect was observed fol-
lowing treatment with IL-1a + TNFa indicating a syner-
gistic action of these two cytokines. MGDG represses
also the IL-6 and IL-8 induction by IL-1a;4 )T h e
Figure 7 15ΔPGJ2 (15-deoxy-Δ
12,14-prostaglandin J2,) represses mPGES (microsomal PGE synthase) expression and PGE2 (prostaglandin
E2) production. A) Human chondrocytes were treated in serum free conditions with 3 μM1 5 ΔPGJ2 for two hours before being incubated with
100 U/ml IL-1a for 24 hours in the presence of 15ΔPGJ2. Cell lysates were subjected to immunoblot analysis using anti mPGES polyclonal
antibodies. Actin was blotted as an internal control; B) Quantitation of mPGES inhibition by5ΔPGJ2 treatment. Quantitation of the inhibition by
15ΔPGJ2 was obtained by the densitometric analysis of three Western blots from three different primary cultures; to show the repression by
15ΔPGJ2 the % value referred to the value in IL-1 induced cells (100%) is calculated. Average ± standard deviation is shown. C) PGE2 production.
Conditioned media collected from human chondrocytes were analyzed for prostaglandin E2 content by a competitive immunoassay using the
prostaglandin E2 EIA kit Monoclonal. Two experiments were performed in triplicate dishes, each one assayed in triplicate. One representative
experiment is shown. Concentrations are expressed in pg/ml. 15ΔPGJ2, 15-deoxy-Δ
12,14-prostaglandin J2,; COX-2, cyclooxygenase-2; DGDG,
digalactosyldiacylglycerol; IL-1, interleukin-1; IL-6, interleukin-6; IL-8, interleukin-8; MGDG, monogalactosyldiacylglycerol; mPGES, microsomal PGE
synthase; NF-kB, nuclear factor-kappaB; P1, cell passage number1; p38, p38 mitogen activated protein kinase; PGE2, prostaglandin E2; TNFa, tumor
necrosis factor alpha.
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Page 9 of 12inflammatory pathway leading to the expression of IL-6
and IL-8 following treatment with IL-1a involves the
p38 and NF-kB pathways; 5) MGDG inhibits the p38
activation induced by IL-1a and partially but signifi-
cantly decreases the NF-kB activation; 6) MGDG
enhances the COX-2 expression induced by IL-1a +
TNFa or IL-1a in cultured human articular
chondrocytes.
This last point deserves attention because it is unex-
pected. Indeed, COX-2 is induced in inflammation and
is considered one of the factors triggering an inflamma-
tory response [29]. The fact that IL-6 and IL-8 are
repressed by MGDG while COX-2 is induced suggested
to us that COX-2 products could modulate the expres-
sion of IL-6 and IL-8. Because of that, we studied the
expression of mPGES and measured the production of
PGE2 and we showed in vitro that mPGES expression as
well as PGE2 production were induced by IL-1a and
repressed by the MGDG treatment. COX-2 is an
enzyme with a well-known pro-inflammatory role as the
inflammatory reaction develops concomitant to an
increase of PGE2, but there is also evidence of its anti-
inflammatory role during the resolution phase associated
with the production of 15ΔPGJ2 [19,30,31]. In a recent
paper from our laboratory an anti-inflammatory activity
of 15ΔPGJ2 in the resolution of inflammation in the
mouse chondrocytic cell line MC615 was described,
showing that 15ΔPGJ2 was able to repress the inflamma-
tory response to LPS possibly by PPARg activation [13].
Measuring the concentration of 15ΔPGJ2 following the
treatment of cartilage cells with MGDG in inflammatory
condition we have detected a strong increase of
15ΔPGJ2 with respect to the control. Because of that, we
treated cartilage cells with IL-1a in the absence and
Figure 8 Model for interactions possibly occurring in cultured articular chondrocytes during inflammation and resolution of
inflammation.1 5 ΔPGJ2, 15-deoxy-Δ
12,14-prostaglandin J2,; COX-2, cyclooxygenase-2; DGDG, digalactosyldiacylglycerol; IL-1, interleukin-1; IL-6,
interleukin-6; IL-8, interleukin-8; MGDG, monogalactosyldiacylglycerol; mPGES, microsomal PGE synthase; NF-kB, nuclear factor-kappaB; P1, cell
passage number1; p38, p38 mitogen activated protein kinase; PGE2, prostaglandin E2; TNFa, tumor necrosis factor alpha.
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Page 10 of 12presence of 15ΔPGJ2,a n dw es h o w e din vitro that this
prostaglandin repressed the synthesis of IL-6 and IL-8
induced by IL-1a. In the same cells mPGES, induced by
IL-1a, was repressed, suggesting the presence of an
anti-inflammatory pathway that drives prostaglandin
synthesis toward the synthesis of PGD2 and its deriva-
tives. This hypothesis is supported by literature data
showing that, in chondrocytes, 15ΔPGJ2 inhibited the
expression of mPGES and PGE2 production induced by
IL-1a [32]. In human mesangial cells (HMC) pre-incu-
bation with 15ΔPGJ2 inhibited IL-1a-induced PGE2 pro-
duction although IL-1a-induced COX-2 expression
remained unaffected, indicating that 15ΔPGJ2 inhibits
PGE2 production independently of its effect on COX-2
expression [33]. In osteoarthritic cartilage 15ΔPGJ2
repressed the synthesis of mPGES induced by IL-1a
while COX-2 was only partially inhibited [34]. In addi-
tion, in the chronic model of collagen-induced arthritis
the administration of a novel inhibitor of the mPGES
expression clearly reduced PGE2 and mPGES expression
in joint tissues, whereas COX-2 was unaffected [35].
MGDG represses mPGES, lowers PGE2 production,
enhances COX-2 expression and induces 15ΔPGJ2 pro-
duction; likely it activates the anti-inflammatory pathway
triggered by 15ΔPGJ2 possibly important in inflamma-
tion resolution.
Conclusions
I ns u m m a r yw eh e r er e p o r tt h a tM G D Gh a sap o t e n t
anti-inflammatory activity in vitro in cultured articular
chondrocytes through the p38 and NF-KB pathways
inhibition. In addition, MGDG could possibly activate
an anti-inflammatory pathway involving 15ΔPGJ2. A car-
toon rendition of the interactions proposed to occur
during the inflammation and the inflammation resolu-
tion phases between the proteins and the factors consid-
ered in this manuscript is presented in Figure 8.
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